Key result
HCV clearance with direct-acting antivirals is linked to reduced cardiovascular events and improved atherosclerosis.
Answers are grounded in this paper and cite their sources.
Hepatitis C virus (HCV) infection is associated with extrahepatic manifestations, among these there is an increased risk of atherosclerosis and cardiovascular disease as well as an increased cardiovascular mortality. Several direct and indirect HCV pro-atherogenic mechanisms have been proposed. HCV lives and replicates within carotid plaques, promoting a local environment of pro-atherogenic factors. In addition, it causes conditions such as insulin resistance, diabetes, hepatic steatosis, cryoglobulinemia and endotoxinemia that are associated with the development of atherosclerosis and cardiovascular disease. Therapeutic regimens based on direct-acting antiviral agents (DAA) are currently available with high efficacy in HCV clearance and improvement of liver disease, but does HCV eradication also improve atherosclerosis and the risk of cardiovascular disease? Recently, a multi-center study has shown that elimination of HCV improves carotid atherosclerosis. Two studies have shown that DAA treatments significantly reduce the risk of cardiovascular events. Several studies have assessed the impact of HCV clearance on pro-atherosclerosis metabolic conditions showing improvement in cardiovascular risk biomarkers, disappearance or improvement of insulin resistance, reduction of risk of developing diabetes and improvement of glycemic control. There are also evidences that HCV clearance promotes the recovery of cytokines and inflammatory markers associated with atherosclerosis and the disappearance of cryoglobulinemia. Available data show that clearance of HCV by DAAs is associated with an improvement in atherosclerosis and metabolic and immunological conditions that promote the development of cardiovascular disease. However, the data are not sufficient to allow definitive conclusions and further studies will be needed to definitively clarify the impact of HCV clearance on atherosclerosis and cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Adinolfi et al. (2018) conducted a review in Chronic hepatitis C virus infection, atherosclerosis, and cardiovascular disease. Direct-acting antiviral agents (DAA) was evaluated on Atherosclerosis and risk of cardiovascular disease. Direct-acting antiviral therapy clearing HCV is associated with improved carotid atherosclerosis, pro-atherogenic metabolic conditions, and reduced cardiovascular events across reviewed studies.
Synapse has enriched 10 related papers. Consider them for comparative context: